A THEROSCLEROSIS IS THE leading cause of mortality in developed countries, accounting for nearly 50% of all deaths. Both environmental and genetic factors contribute to the development of atherosclerosis. Epidemiological studies have identified high levels of low-density lipoprotein (LDL) cholesterol and decreased levels of high-density lipoprotein (HDL) cholesterol as major contributors to atherogenesis (1, 2) . As a result, many current therapies for the treatment of atherosclerosis, notably the statin class of lipid-lowering drugs, are aimed at lowering plasma LDL cholesterol. Statins are not a cure, however, and the development of additional agents is needed. Attractive therapeutic strategies for intervention in cardiovascular disease include elevation of plasma HDL levels and reduction of vascular inflammation. Drugs that accomplish one or both of these goals may represent the future of cardiovascular medicine.
A particularly attractive point for intervention in atherosclerosis is the so-called reverse cholesterol transport pathway (3) . In this process, HDL carries cholesterol from peripheral tissues to the liver, where it can be secreted directly into bile or converted to bile acids.
Although the atheroprotective effects of elevated HDL levels are likely to involve multiple mechanisms, the importance of HDL in reverse cholesterol transport is thought to be a major contributor. Several lines of evidence indicate that reverse cholesterol transport is important for removing cholesterol from the actual site of atherogenesis in the vasculature. In the setting of hypercholesterolemia, macrophages in the artery wall accumulate large amounts of cholesterol ester derived from the scavenging of oxidized LDL cholesterol (1, 2) . Although some can be converted to 27-hydroxycholesterol, cells rid themselves of most of this free cholesterol through efflux to acceptor apolipoproteins (Apos), such as ApoAI and ApoE. The resulting pre-HDL particle is subsequently converted to HDL and transported to the liver, where it is taken up by scavenger receptor type BI (SR-BI). The elucidation of the molecular mechanisms involved in reverse cholesterol transport has led to the identification of new targets for raising HDL levels and limiting the development of cardiovascular disease. This review will focus on two potential targets, the nuclear receptors LXR␣ and LXR␤. metabolic pathways. Both LXR␣ and LXR␤ are activated by physiological concentrations of sterol metabolites such as 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 27-hydroxycholesterol, and 24(S), 25-epoxycholesterol (4-6). The two LXRs share considerable sequence homology and appear to respond to the same endogenous ligands. Their tissue distribution differs, however. LXR␣ is highly expressed at in liver, adipose tissue, and macrophages, whereas LXR␤ is expressed in all tissues examined (7) . Similar to other members of the nuclear receptor family, these proteins contain a zinc finger DNA-binding domain and a ligand-binding domain that accommodates specific small lipophilic molecules. Ligand binding triggers a conformational change that promotes interaction with coactivator proteins and facilitates the activation of specific target genes. LXRs bind to their target DNA sequences in heterodimeric complexes with the retinoid X receptor (RXR) (8) . LXR/RXR is a so-called permissive heterodimer, in that it can be activated by ligands for either LXR or RXR.
Mice carrying targeted disruption of the LXR genes have been invaluable tools for the dissection of LXR biology (9, 10) . The first LXR target to be identified was CYP7A1, the enzyme that catalyzes the rate-limiting step in bile acid synthesis. The inability of LXR␣ null mice to appropriately regulate this gene provided the first clue to function of LXRs in cholesterol metabolism (10) . On a high-cholesterol diet, LXR␣ null mice exhibit dramatically increased plasma LDL cholesterol and decreased HDL cholesterol levels. Conversely, administration of a synthetic LXR agonist to a mouse receiving no dietary cholesterol results in a substantial increase in the fecal excretion of neutral sterols (11) . Cholesterol loss in the mouse also results in part from an increase in conversion to bile acids due to enhanced expression and activity of the CYP7A1 gene. LXR agonists would not be expected to promote bile acid synthesis in humans, however, as the LXR response element is not conserved in the promoter of the human CYP7A1 gene (12) .
Since the discovery of CYP7A1, an array of additional LXRs targets has been identified. Not surprisingly, many of these genes have clear links to lipid metabolism (schematized in Fig. 1 ). Characterization of these new LXR targets has expanded our understanding of the role of LXRs in lipid homeostasis and has fueled speculation as to how regulation of these genes by LXR ligands might impact the development of atherosclerosis. Below, we review a number of re-cently characterized LXR target genes and discuss their potential physiological and pathophysiological relevance. We also discuss recent in vivo studies that directly link the LXR signaling pathway to the development of cardiovascular disease.
ATP BINDING CASSETTE (ABC) TRANSPORTERS
The observations that synthetic LXR agonists raise plasma HDL cholesterol levels and inhibit intestinal cholesterol absorption in mice (13, 14) has triggered substantial interest in LXR ligands as potential therapeutics. These desirable effects on systemic cholesterol homeostasis would be predicted to have a beneficial impact on cardiovascular disease. Considerable evidence implicates members of the ABC transporter family of proteins in these LXR effects. ABC transporters are integral membrane proteins that couple the hydrolysis of ATP to the transport of various substrates across cellular membranes. A particularly important LXR target gene is ABCA1. The ABCA1 protein is critical for the efflux of excess cellular cholesterol to Apo acceptors such as ApoAI, the first step in reverse cholesterol transport. The importance of ABCA1 in systemic cholesterol metabolism has become clear from the study of patients with Tangier disease, which is caused by mutations in this gene (15) (16) (17) . Tangier disease is characterized by the absence of plasma HDL and the accumulation of cholesterol esters in the reticuloendothelial cells of peripheral tissues including tonsils, spleen, lymph nodes, intestinal mucosa, and thymus. Cells from Tangier patients are defective in their ability to efflux cholesterol. Studies in animal models have confirmed an important role for ABCA1 activity in atherosclerosis susceptibility. Although the genetic absence of ABCA1 in an ApoEϪ/Ϫ or LDLRϪ/Ϫ background does not affect the development or composition of atherosclerotic lesions (18) , this is most likely the result of very low plasma cholesterol levels similar to that seen in Tangier patients. Bone marrow transplantation studies have shown that selective inactivation of ABCA1 in macrophages increases atherosclerosis in mice without altering plasma cholesterol levels (19, 20) . Conversely, expression of the human ABCA1 gene in atherogenic mice, either under the direction of its own promoter or the ApoE promoter, reduces the extent of atherosclerotic lesions (21, 22) .
Multiple studies have established the central role of LXRs in the control of ABCA1 expression and cholesterol efflux (13, (23) (24) (25) . Repa et al. (13) established that LXR/RXR heterodimers are key regulators of ABCA1 expression in vivo and showed that ligand activation of LXR inhibits intestinal cholesterol absorption. They also showed that the ability of oxysterol and synthetic LXR activators to stimulate ABCA1 expression is lost in mice lacking LXRs. Costet et al. (23) identified an LXR response element in the promoter of the ABCA1 gene. Venkateswaran et al. and Schwartz et al. (24, 25) demonstrated that ABCA1 mRNA expression is induced in macrophages in response to lipid loading and that expression and activation of LXR stimulates ApoA-I mediated efflux of cholesterol. Importantly, the ability of LXR to stimulate cholesterol efflux is directly related to its ability to control ABCA1 because the effect of LXR ligands is lost in fibroblasts from Tangier patients. The ability of LXR ligands to raise HDL cholesterol levels in mice is consistent with the established function of ABCA1 in reverse cholesterol transport (14) . Finally, LXR␣␤ null mice develop splenomegaly and accumulate foam cells in multiple peripheral tissues, a phenotype remarkably similar to that of the ABCA1 null mice (26, 27) .
Several other ABC transporters have also been identified as LXR targets, including ABCG1, ABCG5, and ABCG8. Similar to ABCA1, expression of ABCG1 is also induced in macrophages in response to cholesterol loading and specific oxysterol LXR ligands (28) . The function of ABCG1 is currently unknown, but it has been proposed to play a role in cholesterol efflux, perhaps by working in concert with ABCA1 (29) . ABCG5 and ABCG8 were recently identified as the genes responsible another rare genetic disorder, sitosterolemia (30, 31) . Patients with this disease exhibit hyperabsorption of cholesterol and show an abnormal capacity to absorb plant sterols from their diet. Patients also show diminished secretion of sterols into bile and hypercholesterolemia and develop premature cardiovascular disease. The ABCG5 and ABCG8 proteins form a dimer that resides in the apical membrane of the hepatocyte and functions to pump cholesterol into bile. Initial studies postulated that ABCA1 may be the key target responsible for LXR inhibition of cholesterol absorption; however, recent studies suggest that ABCG5 and ABCG8 may play a more prominent role in this effect (32, 33) . ABCG5 and ABCG8 expression is enhanced by LXR agonists in mice in a receptor-dependent manner (34) . In accordance with these changes, biliary cholesterol content is increased and cholesterol absorption efficiency is decreased (13, 35) . Similar changes have been observed in transgenic mice overexpressing the human ABCG5 and ABCG8 genes (36) . Finally, the ability of LXR ligands to stimulate biliary cholesterol secretion is preserved in mice lacking ABCA1, consistent with an important role for ABCG5 and ABCG8 in this process (35) .
APOLIPOPROTEINS
ApoE is a principal protein component of chylomicron remnants, very low-density lipoproteins (VLDLs) and intermediate-density lipoproteins. Recognition of ApoE by LDL receptors mediates hepatic uptake of these particles (37) . In addition to the liver, ApoE is expressed by a number of peripheral tissues and cell types, including adipose tissue, macrophages, and the brain. Hepatic ApoE expression is controlled by a distal enhancer known as the hepatic control region, whereas expression in macrophages and adipocytes is directed by a distinct flanking sequence termed the multiple enhancer (ME) region (38) . ApoE was the first gene shown to be regulated by LXR/RXR heterodimers in a tissue-specific manner (39) . LXR mediates lipidinducible expression of the ApoE gene in adipose tissue and macrophages but not in liver. This differential regulation correlates with the presence of a critical LXR response element in the ME region of the ApoE gene.
Mice lacking ApoE expression develop atherosclerosis spontaneously on a normal chow diet and are a widely used model for the study of atherogenesis. Due to the importance of ApoE in lipoprotein clearance, mice lacking this protein exhibit greatly elevated plasma VLDL and intermediate-density lipoprotein cholesterol levels (37) . However, several lines of evidence indicate that macrophage expression of ApoE also exerts an antiatherogenic effect. Mice expressing ApoE only in macrophages are protected against atherosclerosis, whereas those specifically lacking ApoE expression in macrophages are more susceptible (40) (41) (42) . As ApoE is present in a gene cluster that contains ApoCI, ApoCII, and ApoCIV, and it was recently demonstrated that these Apo genes are also LXR responsive (43) . Interestingly, all of these ␣-helical secreted Apos have been shown to serve as acceptors in ABCA1-mediated cholesterol efflux. The elaboration of these acceptors by macrophages within the arterial wall would be expected to promote cholesterol efflux and reverse cholesterol transport. The ability of LXR to control expression of the entire ApoCI/ApoCII/ApoCIV cluster may explain why the ability of LXR agonists to inhibit atherosclerosis is not compromised in ApoE null mice (see below).
LIPOPROTEIN REMODELING ENZYMES
LXR has also been shown to influence the expression of several enzymes that act on lipoproteins, including lipoprotein lipase (LPL), cholesterol ester transfer protein (CETP), and the phospholipid transfer protein (PLTP) (44) (45) (46) (47) . LPL catalyzes the hydrolysis of lipoprotein triglycerides and is highly expressed in adipose tissue and muscle, and is also produced by macrophages (48) . Similar to ApoE, the regulation of LPL gene expression by LXR is tissue specific. LXR agonists induce expression of LPL in liver and macrophages but not in adipose tissue (49) . The contribution of LPL expression to atherogenesis is complex and likely to be context dependent. On the one hand, the hydrolysis of triglyceride-rich lipoprotein and the concomitant generation of material for HDL formation would be considered antiatherogenic. Indeed, systemic overproduction of human LPL in atherogenic animal models appears to protect against atherosclerosis and diet-induced atherogenesis (50, 51) . On the other hand, evidence suggests that macrophage expression of LPL in the artery wall may be proatherogenic. LPL plays a role in binding of modified lipoproteins and may promote the conversion of triglyceriderich lipoproteins to cholesterol-rich lipoproteins such as LDL. Macrophage-specific overproduction of LPL accelerates atherosclerosis in both ApoEϪ/Ϫ and LDLRϪ/Ϫ mice (52, 53) . Thus, the tissue site of LPL expression appears to be a key determinant of its effects on atherosclerosis.
The LXR target genes CETP and PLTP and are both remodeling enzymes that transfer lipids between lipoproteins. CETP is secreted by the liver and circulates in plasma principally bound to HDL (54) . CETP mediates the transfer of HDL cholesterol esters to ApoB-containing particles in exchange for triglycerides (55) . The contribution of CETP activity to atherosclerosis susceptibility is not yet clear. One would predict that the transfer of cholesterol ester from mature HDL particles would generate pre-␤-HDL-like particles that would be antiatherogenic. However, overexpression of human CETP in atherosclerotic mice lowers plasma HDL levels and increases lesion formation (56) . PLTP has been identified as a modulator of HDL metabolism and may also be involved in reverse cholesterol transport (57) . During the lipolysis of serum VLDL by LPL, surface remnants containing phospholipids and Apos are transferred by PLTP and contribute to pre-␤-HDL. PLTP can also mediate lipid transfer between HDL particles to produce a small pre-␤-HDL and a large ␣-HDL. Expression of a human PLTP transgene in mice increases production of pre-␤-HDL and enhances hepatic uptake and clearance of cholesterol ester (58, 59 ). In addition, PLTP has recently been shown to be critical for VLDL secretion from the liver. Surprisingly, PLTP-deficient mice exhibit markedly decreased levels of VLDL and LDL on and ApoEdeficient or ApoB-transgenic background (60) . The ability of LXR agonists to raise plasma HDL, VLDL, and triglyceride levels may involve induction of PLTP expression in liver. However, LXR agonists also control PLTP expression in macrophages and this enzyme is expressed at high levels in atherosclerotic lesions (45) . In the context of lesion macrophages, induction of PLTP expression by LXR is likely to be atheroprotective. Increased PLTP expression in the artery wall may serve to generate cholesterol acceptors and therefore contribute to cholesterol efflux. Tissue-specific knockout or bone marrow transplant experiments will be required to dissect the role of PLTP in these different contexts.
LIPOGENESIS
Some of the earliest studies on LXR pointed to an important role for these receptors in the control of fatty acid as well as cholesterol metabolism. Mice carrying a targeted disruption in the LXR␣ gene were noted to be deficient in the expression of sterol regulatory element binding protein 1c (SREBP-1c), fatty acid synthase (FAS), steroyl coenzyme A desaturase 1 (SCD-1), and acyl coenzyme A carboxylase (ACC) (10) . Consistent with these observations, administration of the synthetic LXR ligands to mice triggers induction of the lipogenic pathway and elevates plasma and hepatic triglyceride levels (14, 61) . Although not immediately evident, the regulation of lipogenesis by LXR is consistent with the view of LXR as a cholesterol sensor. Free cholesterol is highly toxic to cells and esterification to fatty acids is an important mechanism for buffering free cholesterol levels. The primary mechanism by which LXR agonists stimulate lipogenesis appears to be through direct activation of the SREBP-1c promoter (62, 63) . In addition to effects on SREBP-1c, direct actions of LXR on certain lipogenic genes such as FAS (61) and PLTP (44, 45) are also likely to contribute to the ability of LXR agonists to cause hypertriglyceridemia. Thus, although they have many beneficial effects on cholesterol metabolism as described above, LXR agonists have certain undesirable effects. At present, the lipogenic activity of LXR agonists represents a significant obstacle to the development of these compounds as drugs.
LXRs AND ATHEROSCLEROSIS
Macrophage cholesteryl ester accumulation in the artery wall reflects a balance between scavenger receptor-mediated uptake and ABCA1-mediated cholesterol efflux. Thus, alterations in this balance that favor lipid removal via the efflux pathway would be predicted to limit foam cell formation and retard atherogenesis. Conversely, interference with the efflux pathway should exacerbate lesion development. Recent studies have directly addressed the role of the LXR signaling pathway in atherosclerosis using mouse models. As should be clear from the studies reviewed above, the diverse actions of LXRs in different tissues present a challenge to dissecting the roles of specific LXR-mediated effects in cardiovascular disease. Although tissue-specific knockouts of LXRs are not yet available, Tangirala and colleagues (27) were able to address the importance of macrophage LXR signaling using bone marrow transplantation studies into ApoEϪ/Ϫ and LDLRϪ/Ϫ mice. This approach allowed an analysis of LXR null macrophages in the setting of normal LXR function in liver and intestine. Transplantation of LXR null bone marrow led to a significant increase in atherosclerotic lesion formation in both ApoE null and LDLR null recipient mice. These studies provide strong evidence that LXR activity in macrophages is an important determinant of susceptibility to atherosclerosis.
Treatment of highly lipid-loaded macrophages in vitro with synthetic LXR ligands leads to a dosedependent increase in LXR target gene expression, suggesting that a similar hyperactivation of the LXR pathway might be achieved within the vessel wall (64) . Direct evidence for the potential utility of LXR activators in atherosclerosis has come from intervention studies in murine models. The LXR agonist GW3965 was shown to decrease lesion area approximately 50% in both ApoE null and LDLR null mice (64) . A similar reduction in atherosclerosis was observed with the RXR agonist LG268 [which activates LXR/RXR as well as FXR/RXR and peroxisomal proliferator-activated protein (PPAR)/RXR] (65). Thus, despite the undesirable effects of LXR agonists on triglyceride levels, the net effect of whole body LXR activation is antiatherogenic. Chronic ligand administration only moderately affected the lipoprotein profile of these mice, suggesting that direct effect of ligand on cells of the artery wall may also be involved in the antiatherogenic effects. Consistent with this idea, ABCA1 and ABCG1 expression in the atherosclerotic aortas of ApoE null mice were significantly higher in mice treated with LXR agonist (64) .
LXRs AND INFLAMMATION
In an effort to further elucidate the molecular basis for the atheroprotective effects of LXRs, recent studies have explored other roles for these receptors in macrophage biology. In addition to their role in lipid metabolism outlined above, macrophages play a central role in innate immunity. They function to scavenge pathogens and apoptotic cells as well as to coordinate the inflammatory response to such stimuli through the production of cytokines, chemokines, and reactive oxygen species. Moreover, atherosclerosis is now recognized to be a chronic inflammatory disease as well as a disorder of lipid metabolism. Inflammatory mediators such as monocyte chemoattractant protein 1, IL-6, and IL-1␤ promote monocyte recruitment and stimulate smooth muscle cell proliferation (66) . Metalloproteinases such as matrix metalloproteinase-9 have been implicated in both lesion remodeling and plaque rupture (67, 68) . Recently, LXR agonists were shown to antagonize the expression of a battery of inflammatory genes in activated macrophages (69) . Consistent with these in vitro effects, LXR null mice exhibit enhanced responses to inflammatory stimuli and LXR ligands reduce inflammation in a murine model of contact dermatitis. In addition, treatment of ApoE mice with LXR agonists reduced the expression of the inflammatory mediator matrix metalloproteinase-9 in atherosclerotic aortas. Taken together, these observations suggest that LXR agonists may exert their antiatherogenic effects not only by promoting cholesterol efflux, but also by acting to limit the production of inflammatory mediators in the artery wall (Fig. 2) . Additional studies will be required to determine the relative contributions of the lipid metabolic and inflammatory effects of LXR in atherosclerosis. The ability of LXRs to modulate inflammatory signaling in other disease contexts is also being explored.
CROSS-TALK WITH OTHER NUCLEAR RECEPTORS
Two other nuclear receptors, RXR and PPAR␥, have also been associated with the pathogenesis of atherosclerosis. Treatment of atherogenic mouse models with RXR or PPAR␥ agonists results in significant decreases in lesion development (65, 70) . Interestingly, both RXR and PPAR␥ impact LXR-regulated pathways. Like many other nuclear receptors, LXRs bind to DNA and activate transcription as heterodimers with RXR. Because LXR/RXR heterodimers are permissive heterodimers that respond to agonists for both receptors, it is not surprising that RXR agonists mimic many of the effects of LXR activators including induction of ABCA1 and reverse cholesterol transport in macrophages (13, 65) . The observation that expression of the LXR␣ gene is responsive to PPAR␥ provided evidence for substantial cross-talk between the PPAR and LXR pathways. Activation of PPAR␥ leads to a direct increase in the expression of both mouse and human LXR␣ via a PPAR binding site in the LXR␣ promoter (71, 72) . As a result of this cross-regulation, PPAR␥ and LXR agonists have additive effects on ABCA1 expression and reverse cholesterol transport in macrophages (71) (72) (73) . Transplantation of PPAR␥ null bone marrow into LDLR knockout mice also increases atherosclerosis (71) , suggesting that PPAR␥-LXR cross-talk may be important for atherosclerosis susceptibility. LXR␣ may be an important downstream target with regards to the antiatherogenic effects of PPAR␥ ligands. Analysis of macrophage-selective LXR knockouts should allow a clear determination of the role of LXRs in mediating the antiatherogenic effects of these other receptors.
PERSPECTIVES
It is now clear that LXRs play an important role in the maintenance of cellular and systemic lipid homeosta- A number of important issues remain to be explored, however. For example, LXRs are also highly expressed in brain and adipose tissue. The role of LXR signaling in these contexts is not yet clear and is a subject of ongoing investigation. Given the close relationship between lipid and glucose metabolism, it is likely that LXRs may play a role in the coordination of glucose, fatty acid, and cholesterol metabolism. Finally, the role of LXRs in tissues such as skin, kidney, and the adrenals will also need to be addressed.
Pharmacological activation of LXRs in vivo by potent and efficacious synthetic ligands leads to a number of favorable changes in lipid metabolism, including promotion of reverse cholesterol transport, elevation of plasma HDL cholesterol, inhibition of cholesterol absorption, and the antagonism of inflammatory signaling. The relevance of these effects for the development of cardiovascular disease is clear from studies showing that synthetic LXR ligands inhibit atherosclerosis in animal models. At the same time, however, the potent lipogenic activity of the current generation of LXR agonists is a significant limitation. From a drug development standpoint, the most desirable LXR agonist would be one that was a strong inducer of ABCA1 and a strong suppressor of inflammatory gene expression yet lacked activity on the SREBP-1c and FAS promoters. Given the fact that LXR␣ is the dominant receptor involved in control of hepatic lipogenesis, an LXR␤-selective agonist might be particularly useful for the modulation of human lipid metabolism. Finally, the recent discovery of the antiinflammatory actions of LXRs raises the questions of whether these effects can be separated from effects on lipid metabolism and whether certain LXR agonists may have utility as antiinflammatory agents.
